Assembly Biosciences (NASDAQ:ASMB) with a ‘Neutral’ rating from HC Wainwright

HC Wainwright maintained its neutral rating on the stock Assembly Biosciences (NASDAQ:ASMB – Free Report) – according to Benzinga, in a research note published on Thursday.

On Friday, May 10, StockNews.com increased its recommendation for Assembly Biosciences from hold to buy.

View our latest stock report on ASMB

Assembly Biosciences Stock Performance

On Thursday, NASDAQ ASMB opened at $15.13. The company has a 50-day simple moving average of $14.21 and a two-hundred-day simple moving average of $12.14. Assembly Biosciences has a 1-year low of $7.69 and a 1-year high of $20.04.

Assembly Biosciences (NASDAQ:ASMB – Get Free Report) released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.66) earnings per share for the quarter, topping the consensus estimate of ($2.74) by $1.08. The company’s revenue was $5.79 million for the quarter. As a group, equities analysts expect Assembly Biosciences to post -12.65 EPS for the current year.

Confidential activity

In other news, Director John G. Mchutchison sold 2,117 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $14.93, for a total value of $31,606.81. Following the completion of the sale, the director now directly owns 19,104 shares of the company’s stock, valued at approximately $285,222.72. The transaction was disclosed in a filing with the Securities and Exchange Commission, which is available on the SEC’s website. Over the last ninety days, insiders have sold 7,580 shares of company stock worth $102,979. Insiders own 5.10% of the company’s shares.

Institutional investors speak out on gathering life sciences

A hedge fund recently bought a new stake in Assembly Biosciences. Marquette Asset Management LLC has acquired a new position in shares of Assembly Biosciences, Inc., according to its latest Form 13F filing with the Securities and Exchange Commission. (NASDAQ:ASMB – Free Report) in the fourth quarter. The company purchased 54,464 shares of the biopharmaceutical company’s stock valued at approximately $45,000. Marquette Asset Management LLC owned about 0.08% of Assembly Biosciences, according to its most recent filing with the Securities and Exchange Commission. Currently, 19.92% of the shares are held by institutional investors.

On the biological sciences of assemblies

(Get the free report)

Assembly Biosciences, Inc, a biotechnology company, is developing drug candidates for the treatment of viral diseases. It is developing ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor in Phase 1a/1b clinical trials for the treatment of recurrent genital herpes; ABI-1179, currently in a Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small-molecule, orally bioavailable hepatitis delta virus entry inhibitor currently in a Phase 1a clinical trial.

Assembly Biosciences Stock Performance

Confidential activity

Institutional investors speak out on gathering life sciences

On the biological sciences of assemblies

Recommended articles